 Analysts at HC Wainwright repeated their Buy rating on Predictive Oncology Inc and 5 price target, noting that the companys artificial intelligence AI platform has executed important early steps and demonstrated promising predictive capability. Minneapolis, Minnesota-based Predictive Oncologys subsidiary Helomics announced initial results in August last year showing that its AI-driven models of genomic data can predict cancer outcomes. 